Cohen S, Butcher G A, Mitchell G H
Bull World Health Organ. 1974;50(3-4):251-7.
The erythrocytic phase of malarial infection provides a potent stimulus for the production of specific malarial antibody. Serologic tests do not provide any indication of immune status, so that much specific antibody has no protective function. The role of serum antibody in acquired malarial immunity has, however, been established by passive transfer tests, and in the case of P. knowlesi by specific inhibition of the cyclic growth of parasites in vitro. The inhibitory antibody appears to combine with merozoites and prevents their attachment to red cells, thus interrupting the cyclic proliferation of the parasite. The inhibitory antibody response is predominantly variant-specific, but cross-reacting antibody occurs in sufficient amount to suppress proliferation of most other variants of the species. The occurrence of cross-immunity between variants is encouraging from the point of view of vaccination. If it were possible to isolate cross-reacting antigens, these could provide the basis for a malarial vaccine effective against erythrocytic forms of the parasite.
疟疾感染的红细胞期对特异性疟疾抗体的产生提供了强大刺激。血清学检测无法提供任何免疫状态的指标,因此许多特异性抗体并无保护功能。然而,血清抗体在获得性疟疾免疫中的作用已通过被动转移试验得以确立,就诺氏疟原虫而言,则是通过体外特异性抑制寄生虫的周期性生长得以证实。抑制性抗体似乎与裂殖子结合并阻止其附着于红细胞,从而中断寄生虫的周期性增殖。抑制性抗体反应主要是变体特异性的,但交叉反应抗体的量足以抑制该物种大多数其他变体的增殖。从疫苗接种的角度来看,变体之间交叉免疫的出现令人鼓舞。如果能够分离出交叉反应抗原,这些抗原可为有效对抗寄生虫红细胞形式的疟疾疫苗提供基础。